Invesco NASDAQ Biotech UCITS ETF Acc / IE00BQ70R696 / A12CCJ / Invesco IM

Last 05/30/2024[1]	Country	Branch	Type of yield	Type
45.38 USD	United States of America	ETF Stocks	reinvestment	Alternative Investm.

- Invesco NASDAQ Biotech UCITS ETF Acc
- Benchmark: IX ETF Akt. Biotechnologie

Risk key figures

SRI	1	2	3	4	**5**	6	7

Mountain-View Funds Rating[2]   EDA[3]
🔺🔺🔺🔺🔺🔺   -

Yearly Performance

2023	+4.18%
2022	-10.48%
2021	-0.38%
2020	+25.92%
2019	+24.61%

Master data

Fund type	Single fund
Category	Equity
Sub category	ETF Stocks
Fund domicile	Ireland
Tranch volume	(05/30/2024) USD 338.24 mill.
Total volume	(05/30/2024) USD 338.24 mill.
Launch date	11/7/2014
KESt report funds	Yes
Business year start	01.12.
Sustainability type	-
Fund manager	Assenagon Asset Management S.A.

Conditions

Issue surcharge	0.00%
Planned administr. fee	0.00%
Deposit fees	0.00%
Redemption charge	0.00%
Ongoing charges	-

Dividends

Other figures

Minimum investment	UNT 1
Savings plan	-
UCITS / OGAW	Yes
Performance fee	0.00%
Redeployment fee	0.00%

Investment company

Invesco IM

Ireland

https://www.invescomanagementcompany.ie

Performance

Performance	1M	6M	YTD	1Y	2Y	3Y	5Y	Since start
Performance	+5.53%	+13.53%	+0.59%	+8.77%	+19.24%	-6.17%	+39.60%	+47.25%
Performance p.a.	-	-	-	+8.75%	+9.20%	-2.10%	+6.89%	+4.13%
Sharpe ratio	5.30	1.38	-0.14	0.30	0.27	-0.27	0.13	0.01
Volatility	16.74%	18.34%	16.89%	16.54%	20.34%	21.95%	24.28%	24.44%
Worst month	-	-6.08%	-6.08%	-6.59%	-6.59%	-11.90%	-11.90%	-21.04%
Best month	-	12.87%	12.87%	12.87%	12.87%	12.87%	14.98%	14.98%
Maximum loss	-4.02%	-11.60%	-11.60%	-14.28%	-17.32%	-38.26%	-38.26%	-

Distribution permission

Austria, Germany, Switzerland

Invesco NASDAQ Biotech UCITS ETF Acc / IE00BQ70R696 / A12CCJ / Invesco IM

Investment strategy

The Fund is a passively managed Exchange-Traded Fund. To achieve the objective the Fund will use unfunded swaps ("Swaps"). These Swaps are an agreement between the Fund and an approved counterparty to exchange one stream of cash flows against another stream but do not require the Fund to provide collateral, on the basis that the Fund has already invested in a basket of equities and equity related securities (namely shares). Please note that the Fund will purchase securities that are not contained in the Index. The performance of the Index is swapped from the counterparty to the Fund in exchange for the performance of equities and equity related securities held by the Fund.

Investment goal

The objective of the Fund is to aim to track the Total Return performance of the NASDAQ Biotechnology Index (the "Index"), less fees, expenses and transaction costs. The Fund"s base currency is USD. The Index is designed to represent the performance of biotechnology and pharmaceutical securities on the NASDAQ Stock Market. The Index is a modified market capitalisation weighted index. The securities eligible for inclusion include common stocks, ordinary shares, ADRs and shares of beneficial interest or limited partnership interests. The Index has approximately 116 components and is rebalanced on a quarterly basis. Investors should note that the Index is the intellectual property of the index provider.

Assessment Structure

Assets

Stocks — 100.00%

Largest positions

Position	%
AMGEN ORD	8.63%
VERTEX PHARMACEUTICALS ORD	8.05%
REGENERON PHARMACEUTICALS ORD	7.95%
GILEAD SCIENCES ORD	7.80%
ASTRAZENECA ADR REP 0.5 ORD	4.87%
MODERNA ORD	4.64%
BIOGEN ORD	3.44%
ILLUMINA ORD	2.15%
ALNYLAM PHARMACEUTICALS ORD	2.00%
BIOMARIN PHARMACEUTICAL ORD	1.68%

Countries

Country	%
United States of America	87.00%
United Kingdom	5.40%
Netherlands	1.60%
France	1.50%
Germany	1.00%
Denmark	1.00%
Canada	0.80%
China	0.80%
Switzerland	0.50%
andere Länder	0.40%

Branches

Healthcare — 100.00%